Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
DTIC-DOME |
| Manufacturer |
|
Bayer Corp, Pharmaceutical Div. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent. |
| Generic Name |
|
Dacarbazine 200mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol. |
| Indications |
|
Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days. |
| Precautions |
|
Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions. |
| How Supplied |
|
Vials (20mL)—12 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
